Mathematical Modelling of Convection Enhanced Delivery of Carmustine and Paclitaxel for Brain Tumour Therapy

Wenbo Zhan, Davis Yohanes Arifin, Timothy KY Lee, Chi-Hwa Wang* (Corresponding Author)

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

28 Citations (Scopus)


Convection enhanced delivery (CED) is a promising method of anticancer treatment to bypass the blood–brain barrier. This paper is aimed to study drug transport under different CED operating conditions.
The convection enhanced delivery of chemotherapeutics to an intact and a remnant brain tumour after resection is investigated by means of mathematical modelling of the key physical and physiological processes of drug transport. Realistic models of brain tumour and its holding tissue are reconstructed from magnetic resonance images. Mathematical modelling is performed for the delivery of carmustine and paclitaxel with different infusion rates, solution concentrations and locations of infusion site.
Modelling predications show that drug penetration can be improved by raising the infusion rate and the infusion solution concentration. The delivery of carmustine with CED is highly localised. High drug concentration only can be achieved around the infusion site. The transport of paclitaxel is more sensitive to CED-enhanced interstitial fluid as compared to carmustine, with deeper penetration into tumour interior. Infusing paclitaxel in the upstream of interstitial fluid flow leads to high spatial averaged concentration and relatively uniform distribution.
Results obtained in this study can be used to guide the design and optimisation of CED treatment regimens.
Original languageEnglish
Pages (from-to)860-873
Number of pages14
JournalPharmaceutical Research
Publication statusPublished - 2 Feb 2017


  • anticancer therapy
  • brain tumour
  • convection enhanced delivery
  • drug transport
  • mathematical model


Dive into the research topics of 'Mathematical Modelling of Convection Enhanced Delivery of Carmustine and Paclitaxel for Brain Tumour Therapy'. Together they form a unique fingerprint.

Cite this